Featured Publications
[89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer
Laforest R, Lapi SE, Oyama R, Bose R, Tabchy A, Marquez-Nostra BV, Burkemper J, Wright BD, Frye J, Frye S, Siegel BA, Dehdashti F. [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer. Molecular Imaging And Biology 2016, 18: 952-959. PMID: 27146421, PMCID: PMC5096950, DOI: 10.1007/s11307-016-0951-z.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerDose-limiting organPositron emission tomographyBreast cancerMSv/MBqOptimal imaging timeHuman radiation dosimetryPET/CT imagesOrgan time activity curvesGreater tumorTime-activity curvesPurposeThe purposeHuman dosimetryEmission tomographyBiodistribution dataEffective dosePatientsAdverse effectsCancerLiverImaging parametersWomenPresent studyTomographyDays[89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer
Lee S, Cavaliere A, Gallezot JD, Keler T, Michelhaugh SK, Belitzky E, Liu M, Mulnix T, Maher SE, Bothwell ALM, Li F, Phadke M, Mittal S, Marquez-Nostra B. [89Zr]ZrDFO-CR011 positron emission tomography correlates with response to glycoprotein non-metastatic melanoma B-targeted therapy in triple negative breast cancer. Molecular Cancer Therapeutics 2022, 21: molcanther.0590.2021. PMID: 35027482, PMCID: PMC8898259, DOI: 10.1158/1535-7163.mct-21-0590.Peer-Reviewed Original ResearchConceptsStandardized uptake valueTriple-negative breast cancerWeeks of treatmentCDX-011Tumor modelBreast cancerMelanoma BPretreatment standardized uptake valueAntibody-drug conjugate (ADC) therapyPatient-derived tumor modelsNegative breast cancerSingle bolus injectionPositron emission tomographyTumor regrewPretreatment PETADC therapyPrognostic markerBolus injectionTumor volumeSUV ratioRadiotracer uptakeUptake valueStrong inverse correlationTumor typesPercent change
2022
Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer
Li Z, Aboian MS, Zhu X, Marquez-Nostra B. Clinical Evaluation of Nuclear Imaging Agents in Breast Cancer. Cancers 2022, 14: 2103. PMID: 35565232, PMCID: PMC9101155, DOI: 10.3390/cancers14092103.Peer-Reviewed Original ResearchPositron emission tomographyBreast cancerMolecular profilingTherapeutic targetSingle photon emission tomography (SPECT) imagingSelection of patientsNuclear imaging agentCustomization of therapyPrecision medicineImaging agentEmission Tomography ImagingMetastatic diseaseClinical evaluationClinical studiesClinical practiceClinical decisionEmission tomographyClinical researchStudy designCancerTomography imagingTherapyDifferent receptorsNoninvasive imagingSPECT agent
2021
Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer
Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B. Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer. Frontiers In Pharmacology 2021, 12: 627693. PMID: 33986665, PMCID: PMC8111013, DOI: 10.3389/fphar.2021.627693.Peer-Reviewed Original ResearchDifferent molecular subtypesBreast cancerPositron emission tomographyMolecular subtypesEmission tomographySingle photon emission tomographyBreast cancer patientsResponse of therapyBreast cancer therapyNew therapeutic agentsPreclinical advancesMolecular imaging methodsCancer patientsCare treatmentCommon cancerPreclinical studiesTherapeutic strategiesCancerDrug resistanceTherapeutic agentsTherapyNew targetsCancer therapyPrecision medicinePatients